Difference between revisions of "Profiles"
Jump to navigation
Jump to search
Line 13: | Line 13: | ||
* [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | * [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | ||
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]] | *[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]] | ||
− | *[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA Profile Checklist: SPECT Profile Conformance]] | + | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA Profile Checklist: SPECT Profile Conformance]] |
==Statements of Endorsement== | ==Statements of Endorsement== |
Revision as of 20:44, 28 April 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
- DWI Profile 2017-04-27 (Public Comment Open)
- DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)
- QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)